Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Desmoplastic Melanoma Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Condition: Multiple Myeloma in Relapse Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc. Recruiting
Condition: Lung Cancer Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Condition: Lymphoma, Mantle Cell Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab; Drug: Placebo in combination with bendamustine and rituximab Sponsor: Acerta Pharma BV Recruiting
Condition: Cluster Detection Interventions: Other: Routine cluster detection; Other: Enhanced cluster detection Sponsors: Harvard Pilgrim Health Care; Hospital Corporation of America (HCA) Healthcare; Brigham and Women's Hospital; University of California, Irvine; Harvard School of Public Health; Rush University; Duke University; University of Massachusetts, Amherst; University of California, San Francisco; Cook County Health & Hospitals System; Centers for Disease Control and Prevention Recruiting
Conditions: Breast Carcinoma; Estrogen Receptor Negative; Progesterone Receptor Negative Interventions: Procedure: Screening Mammography; Procedure: Biospecimen Collection Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Cancer Fatigue; Cancer Survivor; Complete Remission; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8 Interventions: Drug: Bupropion Hydrochloride Controlled-release; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Gary Morrow; National Cancer Institute (NCI) Recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Diabetic Macular Edema Interventions: Device: Retilux; Device: Sham Light Device Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI); Juvenile Diabetes Research Foundation; PhotoOptx LLC Recruiting
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29 Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Vitreomacular Traction (VMT); and Full-thickness Macular Holes (MH) Intervention: Device: Intraocular gas (C3F8) Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI) Recruiting
Condition: Vitreomacular Traction Interventions: Device: Pneumatic Vitreolysis (C3F8 injection); Other: Observation Sponsors: Jaeb Center for Health Research; National Institutes of Health (NIH); National Eye Institute (NEI) Recruiting
Condition: Inflammatory Breast Carcinoma Interventions: Drug: Olaparib; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Chronic Low Back Pain; Chronic Leg Pain Interventions: Device: Therapy A Spinal Cord Stimulation Parameter Set; Device: Therapy B Spinal Cord Stimulation Parameter Set Sponsor: Biotronik, Inc. Recruiting
Condition: Breast Cancer Interventions: Radiation: Radiation; Other: No Radiation Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group Recruiting
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo Administration; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI); NRG Oncology Recruiting
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Stage IB Breast Cancer; Stage II Breast Cancer Interventions: Radiation: regional nodal XRT; Radiation: chestwall XRT; Radiation: WBI Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Radiation Therapy Oncology Group Recruiting